These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21433095)

  • 1. Regenerative medicine: a snapshot of the current regulatory environment and standards.
    Messenger MP; Tomlins PE
    Adv Mater; 2011 Mar; 23(12):H10-7. PubMed ID: 21433095
    [No Abstract]   [Full Text] [Related]  

  • 2. Downgrading of regulation in regenerative medicine.
    Sipp D; Sleeboom-Faulkner M
    Science; 2019 Aug; 365(6454):644-646. PubMed ID: 31416952
    [No Abstract]   [Full Text] [Related]  

  • 3. Balancing Safety and Efficacy With Early Availability in the Regulation of Regenerative Medicine Product.
    Fujiwara Y; Maruyama Y; Honda F
    Clin Pharmacol Ther; 2021 May; 109(5):1182-1185. PubMed ID: 32979224
    [No Abstract]   [Full Text] [Related]  

  • 4. Stem-cell research: after the gold rush.
    Aldhous P
    Nature; 2005 Apr; 434(7034):694-6. PubMed ID: 15815600
    [No Abstract]   [Full Text] [Related]  

  • 5. Governmental Regulations and Increasing Food and Drug Administration Oversight of Regenerative Medicine Products: What's New in 2020?
    Fang WH; Vangsness CT
    Arthroscopy; 2020 Oct; 36(10):2765-2770. PubMed ID: 32442713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. It's about change...regenerative medicine in the Obama era.
    Klein RN; Doyle J; Siegel B
    Regen Med; 2009 Jan; 4(1):27-32. PubMed ID: 19250058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA's claims over stem cells upheld.
    Cyranoski D
    Nature; 2012 Aug; 488(7409):14. PubMed ID: 22859178
    [No Abstract]   [Full Text] [Related]  

  • 8. Purity and the dangers of regenerative medicine: regulatory innovation of human tissue-engineered technology.
    Faulkner A; Kent J; Geesink I; FitzPatrick D
    Soc Sci Med; 2006 Nov; 63(9):2277-88. PubMed ID: 16905231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regenerative medicine, resource and regulation: lessons learned from the remedi project.
    Ginty PJ; Rayment EA; Hourd P; Williams DJ
    Regen Med; 2011 Mar; 6(2):241-53. PubMed ID: 21391857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.
    Plagnol AC; Rowley E; Martin P; Livesey F
    Regen Med; 2009 Jul; 4(4):549-59. PubMed ID: 19580404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Same but Different: Regulation of Tissue Engineering and Regenerative Medicine in the Context of Regional and International Standards and Expectations.
    Williams DF
    Tissue Eng Part A; 2015 Dec; 21(23-24):2781-2. PubMed ID: 26486499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The social production of evidence: regenerative medicine and the 21st Century Cures Act.
    Hogle LF; Das A
    Regen Med; 2017 Sep; 12(6):581-586. PubMed ID: 28976283
    [No Abstract]   [Full Text] [Related]  

  • 13. An embryonic nation.
    Yang X
    Nature; 2004 Mar; 428(6979):210-2. PubMed ID: 15014509
    [No Abstract]   [Full Text] [Related]  

  • 14. Uncertain Oversight of Regenerative Medicines in Japan under the ASRM.
    Lysaght T; Sugii S
    Cell Stem Cell; 2016 Apr; 18(4):438-9. PubMed ID: 27058936
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulatory biocompatibility requirements for biomaterials used in regenerative medicine.
    Williams DF
    J Mater Sci Mater Med; 2015 Feb; 26(2):89. PubMed ID: 25649511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive approval: a proposal for a new regulatory pathway for regenerative medicine.
    Caplan AI; West MD
    Stem Cells Transl Med; 2014 May; 3(5):560-3. PubMed ID: 24682285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rejuvenating Regenerative Medicine Regulation.
    Charo RA; Sipp D
    N Engl J Med; 2018 Feb; 378(6):504-505. PubMed ID: 29320637
    [No Abstract]   [Full Text] [Related]  

  • 18. US FDA outreach to the regenerative medicine community: challenges and opportunities.
    Whittlesey KJ; Witten C
    Regen Med; 2012 Jul; 7(4):595-603. PubMed ID: 22817631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Balancing Safety and Innovation for Cell-Based Regenerative Medicine.
    Marks P; Gottlieb S
    N Engl J Med; 2018 Mar; 378(10):954-959. PubMed ID: 29514023
    [No Abstract]   [Full Text] [Related]  

  • 20. Protecting methods for treatment related to regenerative medicine and gene therapy in Japan.
    Kaneshiro K; Masuda S; Tanaka Y; Tamai K
    Nat Biotechnol; 2004 Mar; 22(3):343-5. PubMed ID: 14990960
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.